- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy ; volume:8 ; number:1 ; day:20 ; month:10 ; year:2023 ; pages:1-2 ; date:12.2023
Signal transduction and targeted therapy ; 8, Heft 1 (20.10.2023), 1-2, 12.2023
- Creator
-
Tian, Xinyu
Zheng, Xiangyun
Tian, Dong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-023-01643-w
- URN
-
urn:nbn:de:101:1-2024013114281338770617
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.03.2025, 6:22 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tian, Xinyu
- Zheng, Xiangyun
- Tian, Dong
- SpringerLink (Online service)
Other Objects (12)
Imaging of tumour response to immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
HNSCC: tumour antigens and their targeting by immunotherapy
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Current status of BAFF targeting immunotherapy in B-cell neoplasm
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Imaging of tumour response to immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
HNSCC: tumour antigens and their targeting by immunotherapy
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Current status of BAFF targeting immunotherapy in B-cell neoplasm
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Imaging of tumour response to immunotherapy
Cancer immunotherapy beyond immune checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
HNSCC: tumour antigens and their targeting by immunotherapy
HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
Samd3 expressing cell contribute critically to checkpoint immunotherapy
Current status of BAFF targeting immunotherapy in B-cell neoplasm
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy